DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADB274629
Title:
Induction of Radiosensitization by Antisense Oligonucleotide Gene Therapy
Corporate Author:
WEST VIRGINIA UNIV RESEARCH CORP MORGANTOWN*
Report Date:
2001-07-01
Abstract:
Protein kinase C PKC promotes cell survival in response to ionizing radiation in a variety of experimental models including human carcinoma, human glioblastoma, and transformed mouse embryo fibroblast cell lines. The purpose of this project is to enhance radiation-induced mammary tumor cell death by inhibition of specific PKC isoforms. Antisense oligonucleotides have been introduced into human breast tumor cell lines to selectively inhibit PKC isoforms. MDA-MB- 231 and MCF-7 cells treated with oligonucleotides directed against PKC isoforms 8 and zeta exhibited impaired survival in response to 5 .6Gy gamma radiation as measured by mitochondrial metabolism of tetrazolium dye. PKC 8 and zeta oligonucleotides were shown to selectively deplete PKC 8 and zeta proteins from cell extracts. Furthermore, a selective PKC 8 inhibitor, rottlerin, impaired survival of cells treated with a therapeutically relevant dose of radiation 1 .5Gy. Treatment of MDA-MB-23 1 cells prior to low dose radiation exposure with PKC 8 oligonucleotide significantly impaired cell survival. The conclusion of this work is that PKC 8 and PKC zeta act as a pro-survival factors in human breast tumor cells in vitro. These findings suggest that down-regulation of PKC 8 and PKC zeta may be a useful approach to radiosensitization in mammary tumors.
Descriptive Note:
Annual summary rept. 1 Jul 2000-30 Jun 2001
Pages:
0050
Contract Number:
DAMD17-99-1-9449
File Size:
2.38MB
